{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:22:44Z","timestamp":1775218964947,"version":"3.50.1"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Hypertension is the predominant pathology underlying nonlobar intracerebral hemorrhage (ICH), and antihypertensive agents have distinct biological implications for cerebral microvasculature. It is unknown if the class of antihypertensive medications initiated after ICH affects functional outcome beyond blood pressure (BP) control.<\/jats:p><\/jats:sec>Objective<\/jats:title>To ascertain the association between the class of antihypertensive agents initiated during hospitalization and 90-day functional outcome in nonlobar ICH.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cohort study uses data from the Ethnic\/Racial Variations of Intracerebral Hemorrhage (ERICH) study, a case-control cohort study investigating ICH risk factors among Hispanic, non-Hispanic Black (hereafter Black), and non-Hispanic White (hereafter White) populations at 42 US hospitals from 2010 to 2015. Data for this analysis were examined from May to September 2024. ERICH study participants were selected for the present analysis if they survived hospitalization and had available covariate and outcome data. Individuals with complications that would limit antihypertensive choice were excluded.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Initiation of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), calcium channel blocker, \u03b2-blocker, thiazide diuretic, and other antihypertensive medications during index hospitalization.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary outcome was a favorable functional outcome, defined as a 90-day (follow-up) modified Rankin Score score of 0 to 2 (score range: 0 [indicating no disability] to 6 [indicating death]). Mixed-effects logistic regression adjusted for demographic characteristics, medical history, ICH characteristics, BP measurement, total number of antihypertensive medications, and hospitalization site was used to calculate the odds of favorable functional outcome.<\/jats:p><\/jats:sec>Results<\/jats:title>Of the 1561 ERICH study participants in the analytic cohort, 1079 had nonlobar and 482 had lobar ICH. Among the 1079 participants in the nonlobar ICH group (mean [SD] age, 58.5 [12.9] years; 676 males [62.6%]; 429 Hispanic [39.8%], 388 Black [36.0%], and 262 White [24.4%] individuals), a total of 407 (37.7%) ACEIs or ARBs, 419 (38.8%) \u03b2-blockers, 503 (46.6%) calcium channel blockers, 180 (16.7%) thiazide diuretics, and 277 (25.7%) other antihypertensive classes were initiated during hospitalization (median [IQR], 3 [2-3] agents at discharge). At follow-up, 481 participants (44.6%) had a favorable functional outcome. Initiation of ACEI or ARB was associated with higher odds of favorable functional outcome (adjusted OR [AOR], 1.49; 95% CI, 1.08-2.05; P<\/jats:italic>\u2009=\u2009.01). No other antihypertensive class was associated with functional outcome. Findings were consistent across several sensitivity analyses. The interaction with ACEI or ARB was mediated by the presence of radiographic features of cerebral small vessel disease (AOR, 3.04; 95% CI, 1.01-9.19; P<\/jats:italic>\u2009=\u2009.049). No association with class of antihypertensive agent was observed in lobar ICH.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This large cohort study found that initiation of ACEI or ARB was associated with favorable 90-day functional outcomes after nonlobar ICH. This finding supports a medication class\u2013specific benefit in hypertensive arteriopathy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.57770","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:00:58Z","timestamp":1738598458000},"page":"e2457770","source":"Crossref","is-referenced-by-count":4,"title":["Antihypertensive Medication Class and Functional Outcomes After Nonlobar Intracerebral Hemorrhage"],"prefix":"10.1001","volume":"8","author":[{"given":"Mohamed","family":"Ridha","sequence":"first","affiliation":[{"name":"Department of Neurology, The Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padmini","family":"Sekar","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Hannawi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"17","key":"zoi241615r1","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMra2201449","article-title":"Spontaneous intracerebral hemorrhage.","volume":"387","author":"Sheth","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi241615r2","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1212\/WNL.0b013e318276896f","article-title":"Risk factors for intracerebral hemorrhage differ according to hemorrhage location.","volume":"79","author":"Martini","year":"2012","journal-title":"Neurology"},{"issue":"19","key":"zoi241615r3","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1161\/CIRCULATIONAHA.116.024073","article-title":"Untreated hypertension: a powerful risk factor for lobar and nonlobar intracerebral hemorrhage in Whites, Blacks, and Hispanics.","volume":"134","author":"Walsh","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"zoi241615r4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020392","article-title":"Impact of uncontrolled hypertension at 3 months after intracerebral hemorrhage.","volume":"10","author":"Biffi","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"zoi241615r5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1001\/jama.2015.10082","article-title":"Association between blood pressure control and risk of recurrent intracerebral hemorrhage.","volume":"314","author":"Biffi","year":"2015","journal-title":"JAMA"},{"issue":"7","key":"zoi241615r6","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1161\/STROKEAHA.121.036885","article-title":"Review of long-term blood pressure control after intracerebral hemorrhage: challenges and opportunities.","volume":"53","author":"Mullen","year":"2022","journal-title":"Stroke"},{"issue":"7","key":"zoi241615r7","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association.","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"issue":"1","key":"zoi241615r8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1161\/HYPERTENSIONAHA.122.18085","article-title":"Hypertension, neurovascular dysfunction, and cognitive impairment.","volume":"80","author":"Santisteban","year":"2023","journal-title":"Hypertension"},{"issue":"2","key":"zoi241615r9","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1161\/01.STR.0000115162.16321.AA","article-title":"Hypertension, angiotensin, and stroke: beyond blood pressure.","volume":"35","author":"Iadecola","year":"2004","journal-title":"Stroke"},{"issue":"8","key":"zoi241615r10","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/STROKEAHA.121.037997","article-title":"Effect of antihypertensives by class on cerebral small vessel disease: a post hoc analysis of SPRINT-MIND.","volume":"53","author":"Goldstein","year":"2022","journal-title":"Stroke"},{"issue":"11","key":"zoi241615r11","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1161\/CIRCULATIONAHA.104.501163","article-title":"Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy.","volume":"112","author":"Dufouil","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"zoi241615r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.21921","article-title":"Ethnic and racial variation in intracerebral hemorrhage risk factors and risk factor burden.","volume":"4","author":"Kittner","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi241615r13","doi-asserted-by":"publisher","first-page":"e353","DOI":"10.1212\/WNL.0000000000009814","article-title":"Genetically determined blood pressure, antihypertensive drug classes, and risk of stroke subtypes.","volume":"95","author":"Georgakis","year":"2020","journal-title":"Neurology"},{"issue":"10","key":"zoi241615r14","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1161\/STROKEAHA.112.661603","article-title":"SMASH-U: a proposal for etiologic classification of intracerebral hemorrhage.","volume":"43","author":"Meretoja","year":"2012","journal-title":"Stroke"},{"issue":"10","key":"zoi241615r15","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1161\/STROKEAHA.113.002332","article-title":"The Ethnic\/Racial Variations of Intracerebral Hemorrhage (ERICH) study protocol.","volume":"44","author":"Woo","year":"2013","journal-title":"Stroke"},{"issue":"12","key":"zoi241615r16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"6","key":"zoi241615r17","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"8","key":"zoi241615r18","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1161\/01.STR.30.8.1538","article-title":"Use of the Barthel Index and modified Rankin scale in acute stroke trials.","volume":"30","author":"Sulter","year":"1999","journal-title":"Stroke"},{"issue":"7","key":"zoi241615r19","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/CIRCRESAHA.118.313260","article-title":"Neurovascular and cognitive dysfunction in hypertension.","volume":"124","author":"Iadecola","year":"2019","journal-title":"Circ Res"},{"issue":"6","key":"zoi241615r20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s12975-023-01195-9","article-title":"Cerebral small vessel disease: a review of the pathophysiological mechanisms.","volume":"15","author":"Hannawi","year":"2024","journal-title":"Transl Stroke Res"},{"issue":"1","key":"zoi241615r21","doi-asserted-by":"publisher","first-page":"H397","DOI":"10.1152\/ajpheart.00679.2010","article-title":"The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension.","volume":"300","author":"Capone","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"zoi241615r22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/01.ATV.0000253885.41509.25","article-title":"Cerebrovascular nitrosative stress mediates neurovascular and endothelial dysfunction induced by angiotensin II.","volume":"27","author":"Girouard","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"zoi241615r23","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1161\/01.RES.0000148637.85595.c5","article-title":"Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals.","volume":"95","author":"Kazama","year":"2004","journal-title":"Circ Res"},{"issue":"3","key":"zoi241615r24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/FJC.0b013e3181e8af62","article-title":"Captopril treatment temporarily restores cerebral blood flow autoregulation in spontaneously hypertensive rats after hemorrhagic stroke.","volume":"56","author":"Davis","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"issue":"10","key":"zoi241615r25","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1161\/01.STR.31.10.2478","article-title":"Angiotensin II AT1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats.","volume":"31","author":"Nishimura","year":"2000","journal-title":"Stroke"},{"issue":"14","key":"zoi241615r26","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1161\/01.CIR.101.14.1653","article-title":"Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.","volume":"101","author":"Schiffrin","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"zoi241615r27","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1161\/01.STR.0000129788.26346.18","article-title":"Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats.","volume":"35","author":"Ando","year":"2004","journal-title":"Stroke"},{"issue":"6","key":"zoi241615r28","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/00005344-199424060-00011","article-title":"Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation.","volume":"24","author":"Fernandez","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"zoi241615r29","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1096\/fj.04-2960fje","article-title":"Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury.","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J"},{"issue":"8","key":"zoi241615r30","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.12252","article-title":"Effects of candesartan vs lisinopril on neurocognitive function in older adults with executive mild cognitive impairment: a randomized clinical trial.","volume":"3","author":"Hajjar","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi241615r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45319","article-title":"Association of antihypertensives that stimulate vs inhibit types 2 and 4 angiotensin II receptors with cognitive impairment.","volume":"5","author":"Marcum","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi241615r32","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jacc.2003.10.060","article-title":"Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials.","volume":"43","author":"Fournier","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"zoi241615r33","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1097\/HJH.0b013e32814a5ae5","article-title":"Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? a meta-analysis of trials according to treatment with potentially different effects on angiotensin II.","volume":"25","author":"Boutitie","year":"2007","journal-title":"J Hypertens"},{"issue":"11","key":"zoi241615r34","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaneurol.2020.2349","article-title":"A pooled analysis of diffusion-weighted imaging lesions in patients with acute intracerebral hemorrhage.","volume":"77","author":"Murthy","year":"2020","journal-title":"JAMA Neurol"},{"issue":"5","key":"zoi241615r35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00401-020-02140-y","article-title":"Histopathology of diffusion-weighted imaging-positive lesions in cerebral amyloid angiopathy.","volume":"139","author":"Ter Telgte","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"8","key":"zoi241615r36","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1212\/WNL.0000000000003630","article-title":"Ischemic lesions, blood pressure dysregulation, and poor outcomes in intracerebral hemorrhage.","volume":"88","author":"Kidwell","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"zoi241615r37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ana.22668","article-title":"Predictors of highly prevalent brain ischemia in intracerebral hemorrhage.","volume":"71","author":"Menon","year":"2012","journal-title":"Ann Neurol"},{"issue":"7","key":"zoi241615r38","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1161\/STROKEAHA.122.036884","article-title":"Cardiovascular events after intracerebral hemorrhage.","volume":"53","author":"Li","year":"2022","journal-title":"Stroke"},{"issue":"9200","key":"zoi241615r39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"issue":"9287","key":"zoi241615r40","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.","volume":"358","author":"PROGRESS Collaborative Group","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"zoi241615r41","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1161\/01.STR.0000106480.76217.6F","article-title":"Effects of a perindopril-based blood pressure\u2013lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial.","volume":"35","author":"Chapman","year":"2004","journal-title":"Stroke"},{"issue":"2","key":"zoi241615r42","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/STROKEAHA.109.563932","article-title":"Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial.","volume":"41","author":"Arima","year":"2010","journal-title":"Stroke"},{"issue":"6","key":"zoi241615r43","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"issue":"12","key":"zoi241615r44","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events.","volume":"359","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi241615r45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21618","article-title":"Comparison of cardiovascular events among users of different classes of antihypertension medications: a systematic review and network meta-analysis.","volume":"3","author":"Wei","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"15","key":"zoi241615r46","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003302","article-title":"Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke: traditional and bayesian network meta-analysis of randomized trials.","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"zoi241615r47","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1161\/01.STR.0000092488.40085.15","article-title":"Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review.","volume":"34","author":"Rashid","year":"2003","journal-title":"Stroke"},{"issue":"10","key":"zoi241615r48","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1161\/HYPERTENSIONAHA.124.23271","article-title":"Premorbid blood pressure control modifies risk of DWI lesions with acute blood pressure reduction in intracerebral hemorrhage.","volume":"81","author":"Ridha","year":"2024","journal-title":"Hypertension"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2829828\/ridha_2025_oi_241615_1738185894.04759.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T16:01:00Z","timestamp":1738598460000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2829828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.57770","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]}}}